PubRank

Hee Chul Park

Author PubWeight™ 37.11‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003 1.56
2 Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int 2005 1.32
3 Prediction of radiation pneumonitis following high-dose thoracic radiation therapy by 3 Gy/fraction for non-small cell lung cancer: analysis of clinical and dosimetric factors. Jpn J Clin Oncol 2009 1.06
4 Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemoembolization: a prospective evaluation of efficacy and toxicity. Am J Clin Oncol 2010 1.06
5 Salvage treatment with hypofractionated radiotherapy in patients with recurrent small hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2011 1.00
6 Changes of the liver volume and the Child-Pugh score after high dose hypofractionated radiotherapy in patients with small hepatocellular carcinoma. Radiat Oncol J 2012 1.00
7 Prognostic index for portal vein tumor thrombosis in patients with hepatocellular carcinoma treated with radiation therapy. J Korean Med Sci 2011 1.00
8 Can the new American Joint Committee on Cancer staging system predict survival in rectal cancer patients treated with curative surgery following preoperative chemoradiotherapy? Cancer 2012 0.99
9 Predictive factors of gastroduodenal toxicity in cirrhotic patients after three-dimensional conformal radiotherapy for hepatocellular carcinoma. Radiother Oncol 2009 0.99
10 Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung. Acta Oncol 2012 0.99
11 Overexpression of cyclooxygenase-2 is associated with a poor prognosis in patients with squamous cell carcinoma of the uterine cervix treated with radiation and concurrent chemotherapy. Cancer 2002 0.97
12 Clinical results of 3-dimensional conformal radiotherapy combined with transarterial chemoembolization for hepatocellular carcinoma in the cirrhotic patients. Hepatol Res 2003 0.96
13 The prognostic significance of tumor volume regression during radiotherapy and concurrent chemoradiotherapy for cervical cancer using MRI. Gynecol Oncol 2007 0.94
14 Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer 2010 0.93
15 Enrichment of cancer cells from whole blood using a microfabricated porous filter. Anal Biochem 2013 0.92
16 The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma. Liver Int 2014 0.92
17 Scheduled interval trans-catheter arterial chemoembolization followed by radiation therapy in patients with unresectable hepatocellular carcinoma. J Korean Med Sci 2012 0.90
18 The efficacy of high-dose 3-dimensional conformal radiation therapy in patients with small hepatocellular carcinoma not eligible for other local modalities. Am J Clin Oncol 2013 0.90
19 Early changes in apparent diffusion coefficient from diffusion-weighted MR imaging during radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011 0.88
20 The effect of postoperative pelvic irradiation after complete resection of metastatic rectal cancer. J Surg Oncol 2011 0.87
21 Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases? Lung Cancer 2009 0.87
22 High dose involved field radiation therapy as salvage for loco-regional recurrence of non-small cell lung cancer. Yonsei Med J 2012 0.87
23 Sorafenib-triggered radiation recall dermatitis with a disseminated exanthematous reaction. Radiat Oncol J 2013 0.85
24 Factors associated with lateral pelvic recurrence after curative resection following neoadjuvant chemoradiotherapy in rectal cancer patients. Int J Colorectal Dis 2013 0.84
25 Effects of N-acetylcysteine on TEGDMA- and HEMA-induced suppression of osteogenic differentiation of human osteosarcoma MG63 cells. J Biomed Mater Res B Appl Biomater 2011 0.84
26 Negative impact of pretreatment anemia on local control after neoadjuvant chemoradiotherapy and surgery for rectal cancer. Radiat Oncol J 2012 0.83
27 Results and prognostic factors of hypofractionated stereotactic radiation therapy for primary or metastatic lung cancer. J Thorac Oncol 2010 0.83
28 Clinical implications of esophagorespiratory fistulae in patients with esophageal squamous cell carcinoma (SCCA). Med Oncol 2009 0.83
29 Outcome of Local Excision Following Preoperative Chemoradiotherapy for Clinically T2 Distal Rectal Cancer: A Multicenter Retrospective Study (KROG 12-06). Cancer Res Treat 2014 0.83
30 Predictive factors for Child-Pugh score elevation in hepatocellular carcinoma patients treated with conformal radiation therapy: dose-volume histogram analysis. Tumori 2013 0.82
31 Effects of the iron-chelating agent deferoxamine on triethylene glycol dimethacrylate, 2-hydroxylethyl methacrylate, hydrogen peroxide-induced cytotoxicity. J Biomed Mater Res B Appl Biomater 2011 0.81
32 Inhibition of radiation-induced DNA repair and prosurvival pathways contributes to vorinostat-mediated radiosensitization of pancreatic cancer cells. Pancreas 2010 0.80
33 Added value of diffusion-weighted MRI for evaluating viable tumor of hepatocellular carcinomas treated with radiotherapy in patients with chronic liver disease. AJR Am J Roentgenol 2014 0.79
34 Multi-institutional comparison of intensity modulated radiation therapy (IMRT) planning strategies and planning results for nasopharyngeal cancer. J Korean Med Sci 2009 0.79
35 Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. Anticancer Drugs 2010 0.79
36 Enhancement of the ALP activity of C3H10T1/2 cells by the combination of an oxysterol and apatite. Biomed Mater 2010 0.79
37 Adjuvant chemotherapy after neoadjuvant chemoradiation and curative resection for rectal cancer: is it necessary for all patients? J Surg Oncol 2014 0.78
38 Development of the DVH management software for the biologically-guided evaluation of radiotherapy plan. Radiat Oncol J 2012 0.77
39 Mismatch Repair Gene Expression as a Predictor of Tumor Responses in Patients With Rectal Cancer Treated With Preoperative Chemoradiation. Medicine (Baltimore) 2016 0.77
40 In vitro cytocompatibility of N-acetylcysteine-supplemented dentin bonding agents. J Endod 2010 0.76
41 Considerations for radiation therapy in hepatocellular carcinoma: the radiation oncologists' perspective. Dig Dis 2014 0.76
42 Radiation-induced alteration of pain-related signals in an animal model with bone invasion from cancer. Ann N Y Acad Sci 2004 0.76
43 Clinical outcomes of tissue expanders on adjuvant radiotherapy of resected retroperitoneal sarcoma. Medicine (Baltimore) 2016 0.75
44 Child-Pugh score maintenance in cirrhotic hepatocellular carcinoma patients after radiotherapy: aspects of gastroduodenal complications. Tumori 2015 0.75
45 Monte Carlo-based treatment planning for a spoiler system with experimental validation using plane-parallel ionization chambers. Phys Med Biol 2004 0.75
46 Erratum: Acknowledgments correction. Radiat Oncol J 2012 0.75
47 Is Chemoradiotherapy Beneficial for Stage IV Rectal Cancer? Oncology 2015 0.75
48 Development of a video-guided real-time patient motion monitoring system. Med Phys 2012 0.75
49 Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review. Am J Clin Oncol 2012 0.75
50 Salvage radiation therapy for isolated local recurrence of extrahepatic cholangiocarcinoma after radical surgery: a retrospective study. Ann Surg Oncol 2014 0.75
51 Current rectification by spontaneous symmetry breaking in coupled nanomechanical shuttles. Phys Rev Lett 2006 0.75
52 Clinical outcomes of tissue expanders on adjuvant radiotherapy of resected retroperitoneal sarcoma. Medicine (Baltimore) 2016 0.75
53 Decelerated Hot Carrier Cooling in Graphene Non-Dissipative Carrier Injection from MoS. ACS Nano 2020 0.75